CTOs on the Move

Respicardia

www.respicardia.com

 
Founded in 2006 and headquartered near Minneapolis, Minnesota, Respicardia® is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve Respiratory Rhythm Management and cardiovascular health. The remedē® System is an innovative implantable stimulation device designed to restore natural breathing during sleep for patients with Central Sleep Apnea.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.respicardia.com
  • 12400 Whitewater Dr Suite 150
    Minnetonka, MN USA 55343
  • Phone: 952.540.4470

Executives

Name Title Contact Details

Funding

Respicardia raised $58.5M on 12/19/2017

Similar Companies

Dthera

Dthera™ Sciences (OTCQB:DTHR) is the leading digital therapeutic company focusing on the elderly. The San Diego-based, publicly traded company is working to improve the lives of seniors and individuals suffering from neurodegenerative diseases, as well as those who care for them. It has two core products: ReminX™, a commercially available consumer health product for individuals suffering from social isolation and dementia; and DTHR-ALZ, and a development-stage product that has been granted Breakthrough Device designation by the FDA for the mitigation of the symptoms of agitation and depression associated with Alzheimer`s disease.

Biodirection

NanoDx Inc. is a privately held medical device company developing novel and rapid point-of-care technologies for the objective diagnosis and management of concussion and other traumatic brain injury (TBI).

Modesto Radiological Medical

Modesto Radiological Medical is a Modesto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EndoStim

EndoStim is a medical device company focused on the treatment of gastroesophageal reflux disease (GERD) through electrical stimulation of the lower esophageal sphincter. GERD is a condition affects millions of people worldwide and is often not optimally treated despite a maximum drug dosage of medications such as proton pump inhibitors (PPIs). EndoStim’s innovative technology provides a solution addressing the root physiological cause of the disease -- namely a weak or dysfunctional lower esophageal sphincter that allows for reflux into the esophagus.

Animas Corporation

Animas Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.